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Abstract
Background Though enzyme-replacement therapy (ERT)
with alglucosidase alfa has significantly improved the pros-
pects for patients with classic infantile Pompe disease, some
50 % of treated infants do not survive ventilator-free beyond
the age of 3 years. We investigated whether higher and more
frequent dosing of alglucosidase alfa improves outcome.
Methods Eight cross-reactive immunological material
(CRIM) positive patients were included in the study. All had
fully deleterious mutations in bothGAA alleles. Four received
a dose of 20 mg/kg every other week (eow) and four received
40 mg/kg/week. Survival, ventilator-free survival, left-
ventricular mass index (LVMI), motor outcome, infusion-
associated reactions (IARs), and antibody formation were
evaluated.
Results All eight patients were alive at study end, seven of
them remained ventilator-free. The patient who became ven-
tilator dependent was treated with 20 mg/kg eow. Three of the
four patients receiving 20 mg/kg eow learned to walk; two of
them maintained this ability at study end. All four patients
receiving 40 mg/kg/week acquired and maintained the ability
to walk at study end (ages of 3.3–5.6 years), even though their
baseline motor functioning was poorer. There were no appar-
ent differences between the two dose groups with respect to
the effect of ERTon LVMI, the number of IARs and antibody
formation.
Conclusions Our data may suggest that a dose of 40 mg/kg/
week improves outcome of CRIM positive patients over that
brought by the currently recommended dose of 20mg/kg eow.
Larger studies are needed to draw definite conclusions.
Background
Pompe disease (glycogen storage disease type II, OMIM
#232300) is a rare, autosomal recessive lysosomal storage
disorder caused by deficiency of acid α-glucosidase and char-
acterized by lysosomal glycogen storage, mainly in muscle
tissue (Hirschhorn and Reuser 2001). Depending largely on
how much enzyme activity is preserved, it can present at dif-
ferent ages, from soon after birth to late adulthood. Patients
with the classic infantile form present in the first months of life
with generalized muscle weakness, hypertrophic cardiomyop-
athy, respiratory problems, and feeding difficulties (van den
Hout et al 2003). If untreated, they usually die before one year
of age due to cardio-respiratory insufficiency.
Patients’ prospects were significantly improved in 2006,
when enzyme-replacement therapy (ERT) with recombinant
human acid α-glucosidase (Myozyme®, alglucosidase alfa)
was approved. ERT prolongs lifespan, improves cardiac hy-
pertrophy, and enables patients to reach previously unmet mo-
tor milestones (Van den Hout et al 2000, 2004; Kishnani et al
2007, 2009; Chakrapani et al 2010; Hahn et al 2015).
However, response to treatment varies between patients.
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When treated with either 20 or 40 mg/kg every other week
(eow), approximately half of patients with classic infantile
Pompe disease do not survive ventilator-free beyond the age
of 3 years (Kishnani et al 2009). Similarly, a substantial pro-
portion of patients do not learn to walk, and nearly all retain
residual muscle weakness (Muller et al 2009; Case et al 2012;
van Gelder et al 2012). Effective clearance of glycogen from
skeletal muscle is reported in only a small number of patients
(Winkel et al 2003; Van den Hout et al 2004; Thurberg et al
2006; Kishnani et al 2007, 2009). Preclinical studies in mice
(Bijvoet et al 1999; Raben et al 2003) and clinical studies in
infantile patients (Van den Hout et al 2000, 2004; Kishnani
et al 2007, 2009;McVie-Wylie et al 2008) have shown that the
reduction in glycogen levels in skeletal muscle is dose-depen-
dent. On the basis of these findings and of the published in-
tracellular half-life of alpha-glucosidase (Van der Ploeg et al
1988, 1991; Kamphoven 2004; Maga et al 2013), we estimat-
ed that patients might benefit from a higher and more frequent
dose. We therefore treated affected infants with a dose of
40 mg/kg/week, i.e., the dose previously administered to four
infants treated with recombinant human acid α-glucosidase
from rabbit milk (Van den Hout et al 2000, 2004). The safety
and efficacy of this higher and more frequent dosing regimen




Classic infantile Pompe disease was defined as symptoms of
muscle weakness within six months of birth, hypertrophic
cardiomyopathy, and confirmation of total deficiency of acid
α-glucosidase (GAA) activity combined with the finding of
pathogenic mutations in both GAA alleles. From 2009 on we
treated new patients with 40 mg/kg/week. In the current study
we compared patients who started treatment with the recom-
mended dose of 20 mg/kg eow (start before 2009) to patients
who started with a dose of 40 mg/kg/week (start after 2009)
and who had received the treatment for at least 3 years. Data of
this ongoing investigator driven study were included until
April 1 2014; or until a dose change. The study was performed
independent from industry. TheMedical Ethical Committee at
Erasmus MC University Medical Center approved the proto-
cols and all parents gave written informed consent.
None of the patients received immunomodulation. Only
CRIM positive classic infantile patients were included, which
means that the combined set of very severe mutations led to
the production of at least some in-active alpha-glucosidase
protein. Due to the small number of patients no comparative
statistics were applied.
Clinical efficacy
Clinical efficacy was measured by assessing survival,
ventilator-free survival, number of hospitalizations for respi-
ratory infections, cardiac dimensions, and motor function.
Cardiac dimensions were measured by 2D-guided M-mode
echocardiographic tracings (using a Philips iE33 xMAtrix
Echocardiography System, Philips Medical Systems,
Andover, MA, USA), at baseline and at regular intervals
thereafter. Left-ventricular mass index (LVMI) was calculated
as a measure for hypertrophic cardiomyopathy (LVMI>+2z-
scores (Poutanen and Jokinen 2007)) and left ventricular in-
ternal dimension (LVID) as a measure for ventricular dilatation.
Motor function was examined using the Alberta Infant Motor
Scale (AIMS) (Piper and Darrah 1994) and the achievement of
motor milestones was examined at regular clinical
assessments.
Safety
Safety assessments included the monitoring of infusion-
associated reactions (IARs). Adverse events that were judged
to be possibly, probably or definitely related to ERT were
considered to be IARs. The severity of each IAR was indexed
by clinical judgment as mild, moderate or severe (Van den
Hout et al 2004).
Before enzyme infusions, blood samples were drawn at
regular intervals to measure antibodies to ERT with an
enzyme-linked immunosorbent assay (ELISA) (van Gelder
et al 2014).
Pharmacokinetic analysis
To determine the activity of acid α-glucosidase in the blood
circulation and the rate of alglucosidase alfa clearance in rela-
tion to dosing, we measured the activity in plasma during
enzyme infusions with 20 mg/kg and 40 mg/kg. Blood sam-
ples were drawn before the start of the infusion, at 2 and 3 h
after start, at 15 min before the end, at the end of infusion, and
then 15, 30, 60, and 120 min thereafter.
To determine the percentage of the enzyme in the
blood that was antibody-bound, patients’ plasma sam-
ples were incubated in the presence of Protein-A
Sepharose beads to bind antibody-bound alglucosidase
alfa, and in parallel in the presence of Sepharose beads
only (control). After removal of the beads by centrifu-
gation, acid α-glucosidase activity was measured in the
supernatant (de Vries et al 2010). Pre-infusion serum
samples were collected to determine the corresponding
patients’ antibody titers by ELISA (van Gelder et al
2014).
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Results
Patients
We included eight patients with classic infantile Pompe disease,
four of whom were treated with alglucosidase alfa in a dose of
20 mg/kg eow and four with 40 mg/kg/week. The patients’
characteristics are summarized in Table 1. Patients in the
20 mg/kg eow dose group started ERT at a median age of
0.9 months (range 0.1–2.2 months) vs. a median age of
3.1 months (range 0.3–4.6 months) in the 40 mg/kg/week
group. The median age at study end was 4.1 years (range
1.7–9.4 years) in the 20 mg/kg eow dose group and 3.5 years
(range 3.3–5.6 years) in the 40 mg/kg/week dose group. All
patients had very severe mutations in the GAA gene (Table 1,
www.pompecenter.nl).
Clinical efficacy
Survival and ventilator-free survivalAt baseline, four of the
eight patients required supplemental oxygen; 50 % in both
dose groups. Oxygen supply was discontinued in all patients
within months after start of treatment.
At study end, one of the four patients in the 20 mg/kg eow
dose group had developed respiratory insufficiency and became
ventilator dependent at the age of 2.7 years during a pneumonia
incident (Table 1). In the 40 mg/kg/week group none had devel-
oped respiratory insufficiency. All patients are alive.
Hospital admissions for respiratory infections After the
start of ERT, three of the four patients treated with 20 mg/kg
eow were repeatedly hospitalized for respiratory infections or
aspiration pneumonias, the number of admissions ranged from
3 to 5. In the 40 mg/kg/week group none of the patients were
admitted for respiratory infections or aspiration pneumonias
since the start of ERT and all were discharged from hospital
within 3 weeks after the start of ERT.
Cardiac outcome
Median baseline LVMI was similar in both groups; in the
20 mg/kg eow group (median z-score +13.5, range z-score
4.9–21.8) and in the 40 mg/kg/week dose group (median z-
score +21.4, range z-score 6.4–25.8). LVMI steadily de-
creased in both dose groups (Fig. 1a, b). At study end,
LVMI was within normal limits in three of four patients in
the 20 mg/kg eow dose group and in all patients in the
40 mg/kg/week dose group.
Important to note is that one of the patients, treated with
40 mg/kg/week, had severe left-ventricular dilatation and severe
mitral valve regurgitation at baseline, which was considered to
be life threatening by the treating cardiologist. After 1.6 years of
treatment this patient’s LVMI had normalized and mitral regur-
gitation had become moderate. End-diastolic left ventricular in-
ternal dimension (LVIDd) and shortening fraction had also be-
come normal (Kampmann et al 2000; Park 2008).
Motor function
At baseline, all eight patients showed symptoms of muscle
weakness, including head lag and axial hypotonia; six had
AIMS scores below the 5th percentile (2/4 in the 20 mg/kg
eow and 4/4 in the 40 mg/kg/week dose groups (Fig. 1c, d)).
During treatment, seven of the eight patients ultimately
Table 1 Patient characteristics related to infusion-associated reactions (IARs)



















1 M 0.1 33 (2.7)# c.1460 T >C c.1460 T >C 18 (1) 2.9 (0.2) 29.5 (2.5)
2 F 0.5 113 (9.4) c.2481 + 102_2646+ 31del c.2481 + 102_2646 + 31del None NA NA
3 M 1.2 66 (5.5) c.1933G>T c.525delT 27 (0) 3.2 (0.3) 19.9 (1.7)
4 M 2.2 20 (1.7) c.2481 + 102_2646+ 31del c.525delT 3 (1) 8.1 (0.7) 17.3 (1.4)
Total 48 (2)
40 mg/kg/week
5 F 0.3 42 (3.5) c.525delT c.1933G>A 2 (0) 1.4 (0.1) 9.4 (0.8)
6 F 2.4 67 (5.6) c.2481 + 102_2646+ 31del c.2481 + 102_2646 + 31del 70 (6) 0.7 (0.1) 37.6 (3.1)
7 M 3.8 39 (3.3) c.2481 + 102_2646+ 31del c.525delT 10 (0) 0.9 (0.1) 10.3 (0.9)
8 F 4.6 41 (3.4) c.378_379del c.2104C>T 5 (0) 9.7 (0.8) 12.2 (1.0)
Total 87 (6)
M male; F female; eow every other week; IAR infusion-associated reaction; ERT enzyme-replacement therapy, NA not applicable
a Patient developed respiratory insufficiency
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approached the maximal AIMS score and learned to walk: 3/4
in the 20 mg/kg eow dose group (median age at walking
16 months, range 15–17 months), and 4/4 in the 40 mg/kg/
week dose group (median age at walking 15 months, range
14–17 months). Over time, some patients lost motor mile-
stones (Fig. 1c). One patient who had initially learned to walk
lost this skill after becoming ventilator-dependent at the age of
2.7 years. The only patient who did not learn to walk tempo-
rarily lost the ability to attain a sitting position after a respira-
tory syncytial virus infection at the age of 1.3 years. The loss
of motor milestones was observed only in the 20 mg/kg eow
group and not in the 40mg/kg/week dose group. At study end,
two of the four patients in the 20 mg/kg eow group were able
to walk compared to all four patients in the 40 mg/kg/week
group. Yet, muscular problems such as facial-muscle weak-
ness, weakness of the neck flexors, and ankle dorsiflexors




IARs were experienced by 3/4 patients treated with 20 mg/kg
eow and by 4/4 patients treated with 40mg/kg/week (Table 1).
The number of IARs per patient varied substantially. One
patient in the 40 mg/kg/week dose group had 70 IARs (over
50 % of all IARs), six of them were severe. Remarkably, the
IARs started within minutes of the start of the infusion, when
the infusion rate was still slow. Total IgE, serum tryptase,
and complement levels were within the normal range.
Two patients treated with 20 mg/kg eow had one severe
IAR each. The most common IARs were exanthema,
fever, and decreased oxygen saturation. All IARs could
be controlled by slowing the infusion rates and
prolonging the duration of the infusion, with or without
the administration of antihistamines and/or steroids. No
patients discontinued treatment because of IARs, all re-
covered without sequelae, and premedication could be
stopped. At the end of the study, 4/4 patients treated
with 40 mg/kg/week had been IAR-free for at least
1.5 years and all received infusions at home.
Antibody formation
Figure 2a, b shows the antibody titers to alglucosidase alfa of
the two groups over the entire study period. In the 20 mg/kg
eow dose group the median peak antibody titer was 1:6250
(range 1:1250–1:31,250); in the 40 mg/kg/week dose group
the median peak was 1:31,250 (range 1:250–1:156,250).
Fig. 1 Left-ventricular mass
index (LVMI) z-scores and
Alberta infant motor scale scores
over time. The different symbols
represent different patients. LVMI
20 mg/kg eow (a) and 40 mg/kg/
week group (b); The dashed gray
line represents the upper limit of
normal (+2 z-scores). AIMS
20 mg/kg eow (c) and 40 mg/kg/
week group (d). The different
symbols represent different
patients. Gray solid line: p50;
dashed gray line: p90 and p10;
dotted gray line: p5
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Peak antibody titers of patients who started ERT before the
age of 2 months ranged from 1:50–1:6250, those of patients
who started ERT later ranged from 1:31,250–1:156,250
(Fig. 2c).
Pharmacokinetic profile
We studied differences in the pharmacokinetics of
alglucosidase alfa administrations of 20 mg/kg and 40 mg/kg
by giving both doses to the same patient at an interval of
1 week. A 40 mg/kg infusion led to approximately twice the
enzyme activity in plasma as compared to a 20 mg/kg infusion
(Fig. 2d). The plasma half-life seemed independent of the
dose.
Around the time that these experiments were performed,
this patient’s antibody titer was 1:6250. Using a Protein-A
Sepharose based precipitation method, we could not detect
substantial amounts of antibody-bound alglucosidase alfa dur-
ing enzyme infusion (Fig. 2d). Neither could we detect
antibody-bound alglucosidase alfa in the plasma of three other
patients who received 40 mg/kg/week and had antibody titers
ranging from 1:1250 to 1:31,250 (patients 6, 7, and 8) at the
time of investigation.
Dose increase at time of clinical deterioration
In three of the four patients in the 20 mg/kg eow dose group
the dose was increased to 40 mg/kg/week (ages 1.7, 2.7 and
5.5 years). This decision was made because the patients expe-
rienced life threatening respiratory infections leading to respi-
ratory insufficiency in one of them.
After dose increase, respiratory infections disappeared in
two patients. In the third patient, who had become ventilator
dependent, ventilation remained required in supine position
and during respiratory infections during the day. The two pa-
tients who were not able to walk did not regain walking abil-
ity. Patients are all alive 5 years after dose increase.
Discussion
It is unquestionable that the introduction of enzyme replace-
ment therapy has significantly improved the life expectancy of
patients with classic infantile Pompe disease (Van den Hout
et al 2000, 2004; Kishnani et al 2007, 2009; Chakrapani et al
2010). Nevertheless, nearly 50 % of the infants treated do not
survive ventilator-free (Kishnani et al 2007, 2009). In this
Fig. 2 Antibody titers to alglucosidase alfa and enzyme activity in
plasma using doses of either 20 mg/kg or 40 mg/kg. Antibody titers to
alglucosidase alfa over time in 20 mg/kg eow (a) and 40 mg/kg/week
group (b). Peak antibody titers in relation to age at start of ERT. Patients
received either 20 mg/kg eow (squares) or 40 mg/kg/week (asterisks) (c).
Enzyme activity (d): blood samples were collected just before the start of
infusion (0 h) and at regular time intervals thereafter. A dose of 20 mg/kg
(circles) and 40 mg/kg (squares) were given to the same patient (patient
3) at 1 week interval after 5.5 years of therapy (titer 1:6250). Closed
symbols represent total acid α-glucosidase activity in the plasma; open
symbols represent the amount of activity that was not antibody-bound.
The activity in the supernatant was measured with MUGlc and is
expressed in nmol 4 MU liberated per 10 μl supernatant per hour. NB:
Even though the enzyme-activity assay is a standardized and validated
assay there is always a slight variation in the figures obtained. All samples
were analyzed as part of one experiment. The total set of analyses were
performed three times with comparable results
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study we evaluated the efficacy and safety of a higher and
more frequent dosing regimen, which we hoped would im-
prove the patients’ clinical outcome.
Preclinical studies in mice have shown a dose dependent
uptake of alglucosidase alfa in the range from 10 to 100 mg/kg
(Raben et al 2003; Kamphoven 2004; McVie-Wylie et al
2008; Khanna et al 2012). In the very first clinical study in
which we treated classic infantile patients with recombinant
human alpha-glucosidase from rabbit milk, we observed a
similar dose dependent effect in that the alpha-glucosidase
activity in the skeletal muscle only normalized when the dose
was increased from 15 to 20 mg/kg/week to 40 mg/kg/week
(Van den Hout et al 2000, 2004, Winkel et al 2003). It is
known that muscle cells are hard to treat since only a small
fraction of infused enzyme actually reaches the muscle
cells. Further it is by now generally accepted that treat-
ment needs to be started before irreversible muscle dam-
age has occurred. This combined experience was reason
for us to treat patients with a dose of 40 mg/kg/week from
start and not to wait until patients deteriorated. Earlier no
difference in clinical response was found between infan-
tile patients treated with either 20 mg/kg/eow and
40 mg/kg/eow (Kishnani et al 2009). This might be attrib-
uted to the lower dose and larger dose interval. Another
factor that may have played a role is that there were more
CRIM negative patients in the higher dose group
(Kishnani et al 2009; Banugaria et al 2011, van Gelder
et al 2014). CRIM negative patients tend to perform
poorer. We therefore excluded CRIM negative patients
from the current study.
The most notable contrast we observed between the two
dose groups was the difference in overall clinical condition,
which was reflected in the difference in hospital admissions
for the two groups: while none of the patients treated with
40 mg/kg/week had ever had respiratory infections requiring
hospitalization, 3/4 patients treated with 20 mg/kg eow re-
quired frequent readmissions. Consequently, one of these pa-
tients developed respiratory insufficiency at the age of
2.7 years. Our study results suggest that the 40 mg/kg/week
dosing regimen helps to stabilize or improve the respiratory
condition of affected infants better. Similarly, motor function
appeared to be better in the 40 mg/kg/week dose group, all of
whom learned to walk and maintained the ability to do so.
Unlike 3/4 patients treated with 20 mg/kg eow learned to walk
and only 2/4 could still walk at the end of the study. The loss
of motor milestones in the 20 mg/kg eow dose group was
preceded by infections requiring hospital admissions.
Importantly walking was not regained in our patients when
the dose was increased after deterioration. Recently two stud-
ies also reported minor effects of dose increase when patients
perform poorly (Case et al 2015; Hahn et al 2015). It should
also be noted that response to ERT varies between patients
treated with the same dose. This is illustrated by 1/4 patients
treated with the lower dose of 20 mg/kg eow, who performed
well until the end of the follow-up at the age of 9 years.
With regard to cardiac hypertrophy, both dosing reg-
imens worked equally well, which is explained by the
fact that a lower dose is required to correct or prevent
the cardiac hypertrophy compared to the skeletal muscle
weakness (Bijvoet et al 1999; Van den Hout et al 2000;
Raben et al 2003). For the same reason, adults with
Pompe disease with residual α-glucosidase activities of
up to 25 % do not generally develop hypertrophic car-
diomyopathy, while they do have skeletal muscle weak-
ness (Hirschhorn and Reuser 2001).
Although we observed no clear differences in safety
parameters, the small numbers do not allow us to draw
firm conclusions. While nearly all patients in each dose
group experienced IARs the overall number of IARs was
higher in the 40 mg/kg/week dose group. This was large-
ly due to a single patient that had had over 50 % of the
total number of IARs. A similar pattern was observed in
the pivotal trials (Kishnani et al 2007, 2009). The patient
with most IARs in our study had recurrent episodes of
exanthema, coughing and vomiting, occasionally accom-
panied by saturation drops. Remarkably, the IARs started
within minutes of the start of the infusion, when the
infusion rate was still slow. Total IgE, serum tryptase
and complement levels were within the normal range.
While this patient had a relatively high sustained anti-
body titer, the titer was similar to that of other patients
who did not develop as many IARs. At the time of writ-
ing, the patient was receiving home-based enzyme ther-
apy without problems, and time since last IAR was over
2 years.
It is well recognized that therapeutic proteins can
induce an immunological response that neutralizes the
effect of ERT. Three of the four patients treated with
40 mg/kg/week and two of the four treated with 20 mg/
kg eow developed a peak antibody titer of 31,250
which was estimated to be the highest titer without sig-
nificant consequences for ERT at a dose of 40 mg/kg
(van Gelder et al 2014). Using pharmacokinetic studies
in the present study, we could not detect substantial
amounts of antibody-bound alglucosidase alfa during en-
zyme infusion in patients whose antibody titers ranged
from 1:6250 to 1:31,250. One patient receiving 40 mg/
kg/week had a peak antibody titer of 1:156,250, which
later declined to 1:31,250. According to earlier esti-
mates, as much as 54 % of the administered enzyme
(about 10 mg/kg) is antibody-bound at a dose of
20 mg/kg and a titer of 1:156,250 (van Gelder et al
2014). If a similar amount (10 mg/kg) were bound upon
administration of 40 mg/kg, about 30 mg/kg would the-
oretically still be available for uptake in the target
tissues.
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Overall, we found no apparent correlation between the lev-
el of antibodies and the dose of ERT, although patients treated
with 40 mg/kg/week tended to develop higher antibody titers
than those receiving 20 mg/kg eow. This is consistent with a
previous study that compared the level of antibody titers be-
tween patients treated with 20 or 40 mg/kg eow (Banugaria et
al 2011). In line with previous observations (Khallaf et al
2013; van Gelder et al 2014) the patient's peak antibody titer
seemed to be related to the age at start of therapy.
A further point that requires attention is that muscu-
lar problems were still observed in patients treated with
40 mg/kg/week. This may be due to insufficient glyco-
gen clearance. As glycogen also accumulates in neural
tissues, including motor neurons of the spinal cord and
peripheral nerves (Gambetti et al 1971), we cannot ex-
clude the possibility that neurological damage plays a
role as well.
Our study describes a limited number of CRIM positive
patients. We have chosen to report on children who received
at least 3 years ERT in a dose of 40 mg/kg/week. Inclusion of
more patients and longer follow-up will be needed to get the
full picture. So far our group of CRIM positive children
starting on 40 mg/kg/week seems to have a better outcome
than those who started on 20mg/kg eow. Our data suggest that
the 40 mg/kg/week has the best effect when applied from the
start.
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